Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 0.67 |
| ▸ | BCHE | P06276 | 13/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250421 | 0.98 | ACHE (0.69) | ACHEBCHE | |
| Hydrochloric Acid SCHEMBL2578272 | 0.96 | ACHE (0.72) | ACHEBCHE | |
| Bromide SCHEMBL1415219 | 0.96 | ACHE (0.72) | ACHEBCHE | |
| Ammonia Solution, Strong SCHEMBL6704056 | 0.94 | ACHE (0.70) | ACHEBCHE | |
| Ammonia Solution, Strong SCHEMBL6704516 | 0.94 | ACHE (0.70) | ACHEBCHE | |
| Bromide SCHEMBL6704511 | 0.93 | ACHE (0.68) | ACHEBCHE | |
| Hydrochloric Acid SCHEMBL6704052 | 0.93 | ACHE (0.68) | ACHEBCHE | |
| SCHEMBL4234816 | 0.85 | ACHE (0.54) | ACHEBCHE | |
| Bromide SCHEMBL18154065 | 0.80 | ACHE (1.00) | ACHEBCHE | |
| Bromide SCHEMBL20138572 | 0.80 | ACHE (1.00) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004202-A1 | Quaternary ammonium-functionalized-POSS compounds | NDSU RESEARCH FOUNDATION | 2010-01-07 | — | — | US | disclosed |
| US-5883248-A | QUATERNARY AMMONIUM INTERMEDIATES | ROUSSEL UCLAF (FR) | 1999-03-16 | — | — | US | disclosed |
| US-4632800-A | Process for producing a thin film having at least one monomolecular layer of non-amphiphilic molecules | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1986-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004202-A1 | Quaternary ammonium-functionalized-POSS compounds | ARG1, SAE1, RBX1 | ACHE 1569/4885BCHE 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.